In Piazza Affari shines the title of Molmed. The biotech company recorded increases of more than 5% in the late morning, with a much higher than average trading volume, over 5 million units, settling at 0,391 euro per share after having reached a maximum of 0,396 during the morning.
The green light granted by theItalian Drug Agency the possibility of producing medicines dedicated to a specific gene therapy based on genetically modified stem cells, and to a specific cell therapy, intended for marketing in the facility currently operating in Milan.
